195 related articles for article (PubMed ID: 8563869)
1. Bioavailability of controlled release mesalazine (5-ASA) preparations.
Rasmussen SN
J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
[TBL] [Abstract][Full Text] [Related]
2. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
3. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
4. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
5. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
[TBL] [Abstract][Full Text] [Related]
6. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.
Gionchetti P; Campieri M; Venturi A; Rizzello F; Ferretti M; Brignola C; Miglioli M
Aliment Pharmacol Ther; 1996 Aug; 10(4):601-5. PubMed ID: 8853765
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN
Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923
[TBL] [Abstract][Full Text] [Related]
8. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
[TBL] [Abstract][Full Text] [Related]
9. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
10. [DDS preparations of drugs for inflammatory bowel disease].
Takada K
Nihon Rinsho; 1999 Nov; 57(11):2508-15. PubMed ID: 10572421
[TBL] [Abstract][Full Text] [Related]
11. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
Schellekens RC; Stuurman FE; van der Weert FH; Kosterink JG; Frijlink HW
Eur J Pharm Sci; 2007 Jan; 30(1):15-20. PubMed ID: 17085024
[TBL] [Abstract][Full Text] [Related]
12. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
Robinson MG
Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
[TBL] [Abstract][Full Text] [Related]
13. A mesalazine enema for ulcerative colitis.
Drug Ther Bull; 1994 May; 32(5):38-9. PubMed ID: 7635028
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Sandborn WJ; Hanauer SB; Buch A
Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
[TBL] [Abstract][Full Text] [Related]
15. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
[TBL] [Abstract][Full Text] [Related]
16. Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption.
Wiltink EH; Mulder CJ; Stolk LM; Rietbroek R; Verbeek C; Tytgat GN
Scand J Gastroenterol; 1990 Jun; 25(6):579-84. PubMed ID: 2359989
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.
De Vos M; Verdievel H; Schoonjans R; Praet M; Bogaert M; Barbier F
Gut; 1992 Oct; 33(10):1338-42. PubMed ID: 1446856
[TBL] [Abstract][Full Text] [Related]
18. Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.
Takaya T; Sawada K; Suzuki H; Funaoka A; Matsuda K; Takada K
J Drug Target; 1997; 4(5):271-6. PubMed ID: 9169983
[TBL] [Abstract][Full Text] [Related]
19. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
Kovács A
Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
[TBL] [Abstract][Full Text] [Related]
20. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]